AR092568A1 - Derivados triciclicos de quinolinas y de quinoxalinas - Google Patents

Derivados triciclicos de quinolinas y de quinoxalinas

Info

Publication number
AR092568A1
AR092568A1 ARP130103294A ARP130103294A AR092568A1 AR 092568 A1 AR092568 A1 AR 092568A1 AR P130103294 A ARP130103294 A AR P130103294A AR P130103294 A ARP130103294 A AR P130103294A AR 092568 A1 AR092568 A1 AR 092568A1
Authority
AR
Argentina
Prior art keywords
fluorinated
alkyl
alkoxy
ring
alkynyl
Prior art date
Application number
ARP130103294A
Other languages
English (en)
Inventor
Braje Wilfried
Bakker Margot
Hoft Carolin
Drescher Karla
Mack Helmut
Haupt Andreas
Lucia Relo Ana
Koolman Hannes
Xu Ruxu
Zhao Xiaona
Lakics Viktor
Original Assignee
Abbvie Deutschland
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50275085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201310410951.1A external-priority patent/CN104418862A/zh
Application filed by Abbvie Deutschland, Abbvie Inc filed Critical Abbvie Deutschland
Publication of AR092568A1 publication Critical patent/AR092568A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1) donde G es (CR³ᵃR³ᵇ)ₙ; X es NR⁶ o CR⁷R⁸; R¹ se selecciona entre el grupo que consiste en hidrógeno, ciano, alquilo C₁₋₆, alquilo C₁₋₆ fluorado, alquenilo C₂₋₆, alquenilo C₂₋₆ fluorado, alquinilo C₂₋₆, alquinilo C₂₋₆ fluorado, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈ fluorado, alcoxi C₁₋₆, alcoxi C₁₋₆ fluorado, -C(=O)R¹⁰, fenilo, fenil-alquilo C₁₋₂ y un anillo heterocíclico saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros que contiene 1, 2, 3 ó 4 heteroátomos o grupos heteroatómicos seleccionados en forma independiente entre N, O, S, NO, SO y SO₂ y opcionalmente también 1 ó 2 grupos C=O y/o C=S como miembros del anillo, donde las unidades cíclicas en los últimos tres radicales mencionados pueden estar sustituidas con uno o más sustituyentes R¹¹; cada R² se selecciona en forma independiente entre el grupo que consiste en ciano, nitro, alquilo C₁₋₆, alquilo C₁₋₆ fluorado, hidroxialquilo C₁₋₆, alquenilo C₂₋₆, alquenilo C₂₋₆ fluorado, alquinilo C₂₋₆, alquinilo C₂₋₆ fluorado, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈ fluorado, alcoxi C₁₋₆, alcoxi C₁₋₆ fluorado, alcoxi C₁₋₆-alquilo C₁₋₄, hidroxi-alcoxi C₁₋₆, alcoxi C₁₋₆-alcoxi C₁₋₄, alquiltio C₁₋₆, alquiltio C₁₋₆ fluorado, alquil C₁₋₆sulfinilo, alquil C₁₋₆sulfinilo fluorado, alquil C₁₋₆sulfonilo, alquil C₁₋₆sulfonilo fluorado, -NR¹²ᵃR¹²ᵇ, -CH₂NR¹²ᵃR¹²ᵇ, -NR¹²ᵃC(O)R¹⁰, -C(=O)R¹⁰, SO₂NR¹²ᵃR¹²ᵇ, alquil C₁₋₆carboniloxi, alquil C₁₋₆carboniloxi fluorado, fenilo, fenil-alquilo C₁₋₂, fenoxi, fenilsulfonilo, benciloxi y un anillo saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros que contiene 1, 2, 3 ó 4 heteroátomos o grupos heteroatómicos seleccionados en forma independiente entre N, O, S, NO, SO, SO₂, C=O y C=S como miembros del anillo, donde las unidades cíclicas en los últimos seis radicales mencionados pueden estar sustituidas con uno o más sustituyentes R¹¹; R³ᵃ y R³ᵇ, en forma independiente entre sí, se seleccionan entre el grupo que consiste en hidrógeno, ciano, nitro, alquilo C₁₋₆, alquilo C₁₋₆ fluorado, hidroxialquilo C₁₋₆, alquenilo C₂₋₆, alquenilo C₂₋₆ fluorado, alquinilo C₂₋₆, alquinilo C₂₋₆ fluorado, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈ fluorado, alcoxi C₁₋₆, alcoxi C₁₋₆ fluorado, alcoxi C₁₋₆-alquilo C₁₋₄, hidroxi-alcoxi C₁₋₆, alcoxi C₁₋₆-alcoxi C₁₋₄, alquiltio C₁₋₆, alquiltio C₁₋₆ fluorado, alquil C₁₋₆sulfinilo, alquil C₁₋₆sulfinilo fluorado, alquil C₁₋₆sulfonilo, alquil C₁₋₆sulfonilo fluorado, -NR¹²ᵃR¹²ᵇ, -CH₂NR¹²ᵃR¹²ᵇ, -NR¹²ᵃC(O)R¹⁰, -C(=O)R¹⁰, SO₂NR¹²ᵃR¹²ᵇ, alquil C₁₋₆carboniloxi, alquil C₁₋₆carboniloxi fluorado, fenilo, fenil-alquilo C₁₋₂, fenoxi, fenilsulfonilo, benciloxi y un anillo saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros que contiene 1, 2, 3 ó 4 heteroátomos o grupos heteroatómicos seleccionados en forma independiente entre N, O, S, NO, SO, SO₂, C=O y C=S como miembros del anillo, donde las unidades cíclicas en los últimos seis radicales mencionados pueden estar sustituidas con uno o más sustituyentes R¹¹; R⁴ᵃ y R⁴ᵇ, en forma independiente entre sí, se seleccionan entre el grupo que consiste en hidrógeno, ciano, nitro, alquilo C₁₋₆, alquilo C₁₋₆ fluorado, hidroxialquilo C₁₋₆, alquenilo C₂₋₆, alquenilo C₂₋₆ fluorado, alquinilo C₂₋₆, alquinilo C₂₋₆ fluorado, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈ fluorado, alcoxi C₁₋₆, alcoxi C₁₋₆ fluorado, alcoxi C₁₋₆-alquilo C₁₋₄, hidroxi-alcoxi C₁₋₆, alcoxi C₁₋₆-alcoxi C₁₋₄, alquiltio C₁₋₆, alquiltio C₁₋₆ fluorado, alquil C₁₋₆sulfinilo, alquil C₁₋₆sulfinilo fluorado, alquil C₁₋₆sulfonilo, alquil C₁₋₆sulfonilo fluorado, -NR¹²ᵃR¹²ᵇ, -CH₂NR¹²ᵃR¹²ᵇ, -NR¹²ᵃC(O)R¹⁰, -C(=O)R¹⁰, SO₂NR¹²ᵃR¹²ᵇ, alquil C₁₋₆carboniloxi, alquil C₁₋₆carboniloxi fluorado, fenilo, fenil-alquilo C₁₋₂, fenoxi, fenilsulfonilo, benciloxi y un anillo saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros que contiene 1, 2, 3 ó 4 heteroátomos o grupos heteroatómicos seleccionados en forma independiente entre N, O, S, NO, SO, SO₂, C=O y C=S como miembros del anillo, donde las unidades cíclicas en los últimos seis radicales mencionados pueden estar sustituidas con uno o más sustituyentes R¹¹; o R⁴ᵃ y R⁴ᵇ forman juntos un grupo =O ó =S; R⁵ᵃ y R⁵ᵇ, en forma independiente entre sí, se seleccionan entre el grupo que consiste en hidrógeno, deuterio, halógeno, ciano, nitro, hidroxi, alquilo C₁₋₆, alquilo C₁₋₆ fluorado, hidroxialquilo C₁₋₆, alquenilo C₂₋₆, alquenilo C₂₋₆ fluorado, alquinilo C₂₋₆, alquinilo C₂₋₆ fluorado, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈ fluorado, alcoxi C₁₋₆, alcoxi C₁₋₆ fluorado, alcoxi C₁₋₆-alquilo C₁₋₄, hidroxi-alcoxi C₁₋₆, alcoxi C₁₋₆-alcoxi C₁₋₄, alquiltio C₁₋₆, alquiltio C₁₋₆ fluorado, alquil C₁₋₆sulfinilo, alquil C₁₋₆sulfinilo fluorado, alquil C₁₋₆sulfonilo, alquil C₁₋₆sulfonilo fluorado, -NR¹²ᵃR¹²ᵇ, -CH₂NR¹²ᵃR¹²ᵇ, -NR¹²ᵃC(O)R¹⁰, -C(=O)R¹⁰, SO₂NR¹²ᵃR¹²ᵇ, alquil C₁₋₆carboniloxi, alquil C₁₋₆carboniloxi fluorado, fenilo, fenil-alquilo C₁₋₂, fenoxi, fenilsulfonilo, benciloxi y un anillo saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros que contiene 1, 2, 3 ó 4 heteroátomos o grupos heteroatómicos seleccionados en forma independiente entre N, O, S, NO, SO, SO₂, C=O y C=S como miembros del anillo, donde las unidades cíclicas en los últimos seis radicales mencionados pueden estar sustituidas con uno o más sustituyentes R¹¹; donde R⁵ᵃ y R⁵ᵇ no son simultáneamente hidroxi; o R⁵ᵃ y R⁵ᵇ, junto con el átomo de carbono al que están unidos, forman un anillo saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros, donde el anillo puede contener 1, 2, 3 ó 4 heteroátomos o grupos que contienen heteroátomos seleccionados entre O, S, N, SO, SO₂, C=O y C=S como miembros del anillo, y donde el anillo puede estar sustituido con uno o más sustituyentes R¹¹; o R⁵ᵃ y R⁶, junto con los átomos a los que están unidos, forman un anillo heterocíclico saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros, donde el anillo además puede contener 1, 2, 3 ó 4 heteroátomos o grupos que contienen heteroátomos seleccionados entre O, S, N, SO, SO₂, C=O y C=S como miembros del anillo, y donde el anillo puede estar sustituido con uno o más sustituyentes R¹¹; o R⁵ᵃ y R⁷, junto con los átomos de carbono al que están unidos, forman un anillo saturado, parcialmente insaturado o totalmente insaturado de 3, 4, 5, 6, 7 u 8 miembros, donde el anillo puede contener 1, 2, 3 ó 4 heteroátomos o grupos que contienen heteroátomos seleccionados entre O, S, N, SO, SO₂, C=O y C=S como miembros del anillo, y donde el anillo puede estar sustituido con uno o más sustituyentes R¹¹; R⁶ se selecciona entre el grupo que consiste en hidrógeno, ciano, alquilo C₁₋₆, alquilo C₁₋₆ fluorado, alquenilo C₂₋₆, alquenilo C₂₋₆ fluorado, alquinilo C₂₋₆, alquinilo C₂₋₆ fluorado, cicloa
ARP130103294A 2012-09-14 2013-09-13 Derivados triciclicos de quinolinas y de quinoxalinas AR092568A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261701531P 2012-09-14 2012-09-14
US201261701514P 2012-09-14 2012-09-14
US201361793033P 2013-03-15 2013-03-15
CN201310410951.1A CN104418862A (zh) 2013-09-11 2013-09-11 三环喹啉和喹喔啉衍生物

Publications (1)

Publication Number Publication Date
AR092568A1 true AR092568A1 (es) 2015-04-22

Family

ID=50275085

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103294A AR092568A1 (es) 2012-09-14 2013-09-13 Derivados triciclicos de quinolinas y de quinoxalinas

Country Status (26)

Country Link
US (3) US10118926B2 (es)
EP (1) EP2895485A1 (es)
JP (1) JP6290217B2 (es)
KR (1) KR20150056608A (es)
CN (1) CN104995191A (es)
AR (1) AR092568A1 (es)
AU (2) AU2013314279B2 (es)
BR (1) BR112015005743A2 (es)
CA (1) CA2884548A1 (es)
CL (1) CL2015000628A1 (es)
CR (1) CR20150186A (es)
DO (1) DOP2015000058A (es)
EC (1) ECSP15012766A (es)
HK (1) HK1212684A1 (es)
IL (1) IL237726A0 (es)
IN (1) IN2015DN02070A (es)
MX (1) MX2015003364A (es)
NZ (1) NZ631187A (es)
PE (1) PE20150777A1 (es)
PH (1) PH12015500551A1 (es)
RU (1) RU2015113558A (es)
SG (1) SG11201501894VA (es)
TW (1) TW201414735A (es)
UA (1) UA116216C2 (es)
UY (1) UY35029A (es)
WO (1) WO2014041131A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
WO2014113388A1 (en) 2013-01-15 2014-07-24 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA3205777A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
EP3116873B1 (en) 2014-03-14 2018-02-28 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a cyclic radical
WO2015136091A1 (en) 2014-03-14 2015-09-17 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a substituted alkyl radical
BR112016023162B1 (pt) 2014-04-04 2022-11-29 Intra-Cellular Therapies, Inc Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
WO2017132408A1 (en) 2016-01-26 2017-08-03 Intra-Cellular Therapies, Inc. Organic compounds
KR102483124B1 (ko) 2016-03-25 2022-12-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US20200392135A1 (en) * 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US20210009592A1 (en) * 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
WO2023068755A1 (ko) * 2021-10-18 2023-04-27 주식회사 사피엔스바이오 신규한 화합물 및 이를 포함하는 약학적 조성물
KR102600176B1 (ko) * 2021-10-18 2023-11-10 주식회사 사피엔스바이오 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714149A (en) 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
DE69016430T2 (de) 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US6063774A (en) * 1996-12-16 2000-05-16 Warner-Lambert Company Tricyclic quinoxaline derivatives as neuroprotective agents
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
AU2002227170A1 (en) * 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20080146583A1 (en) 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
PL1737850T3 (pl) 2004-04-19 2008-02-29 Symed Labs Ltd Nowy sposób wytwarzania linezolidu i związków pokrewnych
ES2325401T3 (es) 2004-07-20 2009-09-03 Symed Labs Limited Intermedios novedosos para linezolid y compuestos relacionados.
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070225274A1 (en) 2006-03-24 2007-09-27 Wyeth Methods for modulating bladder function
KR20080110759A (ko) * 2006-03-24 2008-12-19 와이어쓰 통증 치료
KR20080105104A (ko) 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
AU2008214774A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as TAAR1 ligands
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
CN102482292B (zh) * 2009-04-23 2017-07-18 Abbvie 公司 5‑ht受体的调节剂和其使用方法
US20140080813A1 (en) * 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives

Also Published As

Publication number Publication date
CN104995191A (zh) 2015-10-21
ECSP15012766A (es) 2017-06-30
MX2015003364A (es) 2016-03-31
EP2895485A1 (en) 2015-07-22
DOP2015000058A (es) 2015-04-15
UA116216C2 (uk) 2018-02-26
CA2884548A1 (en) 2014-03-20
US20200283439A1 (en) 2020-09-10
CR20150186A (es) 2015-08-28
HK1212684A1 (zh) 2016-06-17
SG11201501894VA (en) 2015-04-29
WO2014041131A1 (en) 2014-03-20
PH12015500551A1 (en) 2015-05-04
AU2013314279B2 (en) 2017-11-02
RU2015113558A (ru) 2016-11-10
KR20150056608A (ko) 2015-05-26
US20190071443A1 (en) 2019-03-07
TW201414735A (zh) 2014-04-16
AU2018200572A1 (en) 2018-02-15
UY35029A (es) 2014-04-30
CL2015000628A1 (es) 2015-10-30
PE20150777A1 (es) 2015-06-20
AU2013314279A1 (en) 2015-04-02
JP6290217B2 (ja) 2018-03-07
NZ631187A (en) 2017-03-31
IN2015DN02070A (es) 2015-08-14
IL237726A0 (en) 2015-05-31
BR112015005743A2 (pt) 2017-07-04
US10118926B2 (en) 2018-11-06
JP2015528478A (ja) 2015-09-28
US20140080816A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
AR092568A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
AR090867A1 (es) Compuestos y composiciones plaguicidas y procesos relacionados
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR088534A1 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
CO6290715A2 (es) Derivados de ftalazinona
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
ES2869172T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
CO6700838A2 (es) Compuestos sustituidos de banzamida
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
CR20150268A (es) Compuestos novedosos
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR091185A1 (es) Derivados de 1,2,4-triazol
AR110498A1 (es) DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR090086A1 (es) COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b
PE20151977A1 (es) Nuevos derivados de purina

Legal Events

Date Code Title Description
FB Suspension of granting procedure